[BEHAVIOR OF HEMATIC CRASIS IN PATIENTS AFFECTED BY GENITAL NEOPLASMS, SUBJECTED TO CHEMOTHERAPY WITH A NEW DERIVATIVE OF SARCOLYSIN].
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D035843:Biomedical Research; D001792:Blood Platelets; D001853:Bone Marrow; D004906:Erythrocyte Count; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008558:Melphalan; D010051:Ovarian Neoplasms; D010600:Pharmacology; D013752:Tetracycline; D014116:Toxicology; D002583:Uterine Cervical Neoplasms
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D013752:Tetracycline; D008558:Melphalan
ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; BONE MARROW; CERVIX NEOPLASMS; CLINICAL RESEARCH; ERYTHROCYTE COUNT; LEUKOCYTE COUNT; MELPHALAN; OVARIAN NEOPLASMS; PHARMACOLOGY; TETRACYCLINE; TOXICOLOGIC REPORT
IL COMPORTAMENTO DELLA CRASI EMATICA IN PAZIENTI AFFETTE DA NEOPLASIE GENITALI,  SOTTOPOSTE A TRATTAMENTO CHEMIOTERAPICO CON UN NUOVO DERIVATO DELLA SARCOLISINA.